Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this clinical trial, Omeros is advancing OMS824 toward a Phase 2 clinical program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.

The OMS824 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study. The trial enrolled 64 healthy male subjects; 40 subjects received a single dose and 24 subjects received daily dosing for 7 to 10 days. OMS824 was well tolerated by all subjects, and the only apparent drug-related adverse event was mild somnolence at the highest dose evaluated. No subject had extrapyramidal symptoms (e.g., involuntary muscle movements), which are associated with marketed antipsychotic medications and have been seen with other companies' PDE10 inhibitors at levels of approximately 50-percent engagement of the PDE10 enzyme in the brain. A radiotracer imaging study is underway to confirm the target engagement of OMS824 in human brains.

The study results showed that the pharmacokinetic parameters (Cmax and AUC) increased linearly with the dose and that OMS824 had a long half-life that is consistent with once daily dosing. OMS824 was detected in the cerebrospinal fluid at the expected concentration relative to that in the blood. The drug concentration in the cerebrospinal fluid is predicted to achieve near-complete inhibition of the PDE10 target in the brain. These resul
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... 2014 Natural Clear Vision , a ... his own vision from legally blind to perfect 20/20 vision ... review. , “There is a huge portion of the ... function, and most people just think that’s the way it ... that can be pretty risky at times,” reports Michaels. “This ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... (RA), a complex autoimmune disease that affects 1 ... not only cope with pain, disability and joint ... work, family life and marital functioning. While many ... and disability is common. In addition, some patients ... or side effects. Because of this, there is ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... BASKING RIDGE, N.J., Oct. 19 Hooper Holmes,Inc. ... a proven, standard,method for acquiring the additional health ... applicants. Mature Assessment reflects the trend of ... increased willingness to insure them.,To address these customers, ...
... Skin Treatment to Treat All ... BARRINGTON, Ill., Oct. 19 Steroids have been in ... must be reasons why,people use steroid products on a regular ... of the human body, and it needs to stay healthy. ...
... Host Conference Call and Webcast Same Afternoon, DENVER, ... of functional foods, beverages and nutritional,supplements, today announced that ... the three and nine months, ended September 30,2007, on ... a teleconference the same afternoon beginning at,4:15 PM Eastern ...
... XI,AN, China, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- Mr. Weibing ... (OTC,Bulletin Board: SKBI) ("Skystar") will be featured in ... 24, 2007, at 10:30 a.m.,EST. The interview will ... p.m. EST on,October 24. The interview will ...
... drug is given just once per month, experts say , ... treating anemia in patients with severe kidney disease could help ... , Compared with conventional therapy, giving patients an anti-anemia drug ... concluded Dr. Nathan Levin, of the Renal Research Institute in ...
... ... at TCT 2007 ... Oct. 19 Stereotaxis, Inc. (Nasdaq:,STXS) announced today that it will ... at the,Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington,D.C., October 20 to ...
Cached Medicine News:Health News:Hooper Holmes Introduces Mature Assessment 2Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 3Health News:Skystar Bio-Pharmaceutical Announces Upcoming Interview With WallSt.net ( www.wallst.net ) 2Health News:Simpler Anemia Treatment May Help Kidney Patients 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: